Nifekalant

Drug Profile

Nifekalant

Alternative Names: MS 551; Shinbit

Latest Information Update: 21 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nihon Schering
  • Developer Bayer Yakuhin
  • Class Class III antiarrhythmics; Pyrimidinones; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Arrhythmias

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 28 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Arrhythmias therapeutic trials section
  • 25 May 2005 A study has been added to the adverse events and Arrhythmias therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top